Beneficial effects of protease inhibitors on body composition and energy expenditure: A comparison between HIV-infected and AIDS patients

AIDS

Volumn 13, Issue 17, 1999, Pages 2389-2396

  Pernerstorfer Schoen, Heidemarie ^a,f   Schindler, Karin ^a,e,f   Parschalk, Bernhard ^a   Schindl, Andreas ^a,b,c,d   Thoeny Lampert, Sylvia ^a,b,c,d   Wunderer, Katja ^a,b,c,d,e   Elmadfa, Ibrahim ^a,b,c   Tschachler, Erwin ^a,b,c   Jilma, Bernd ^a,b,c,d  

^a Division of Infectious Diseases   (Austria)

^b Division of Special and Environmental Dermatology   (Austria)

^c Department of Clinical Pharmacology ^*  (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

^f Universitatsklinik fur Dermatologie   (Austria)

Author keywords

AIDS; Antiretroviral therapy; Body composition; HIV; Protease inhibitors; Resting energy expenditure; Viral load

Indexed keywords

DIDANOSINE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BIOENERGY; BODY COMPOSITION; BODY MASS; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; LONGITUDINAL STUDY; MALE; METABOLIC PARAMETERS; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REST; UNIVERSITY HOSPITAL; VIRUS LOAD; VOLUNTEER; WASTING SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BASAL METABOLISM; BODY COMPOSITION; BODY WEIGHT; CASE-CONTROL STUDIES; COHORT STUDIES; DIDANOSINE; ENERGY METABOLISM; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NELFINAVIR; PROSPECTIVE STUDIES; STAVUDINE; VIREMIA;

EID: 0032805147     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00010     Document Type: Article

References (40)

1. Kotler D, Heymsfield SB. HIV infection: a model chronic illness for studying wasting diseases. Am I Clin Nutr 1998, 68:519-520.
2. Macallan DC, Noble C, Baldwin C, el al. Energy expenditure and wasting in human immunodeficiency virus infection. N EnglJMcd 1995, 333:83-88.
3. Ott M, Lembcke B, Fischer H, et al. Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am I Clin Nutr 1993, 57:15-19.
4. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992, 41:1-19.
5. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am 1 Clin Nutr 1985, 42:1255-1265.
6. Chlebowski RT, Crosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am ] Gastroentero/ 1989, 84:1288-1293.
7. Gulick RM. Current antiretroviral therapy: an overview. Qua/ Life Res 1997, 6:471-474.
8. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Eng/1 Med 1997, 337:725-733.
9. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997,11:F101-105.
10. Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIV-relaled wasting. AIDS 1998, 12:1777-1784.
11. Sherer R. Current antiretroviral therapy and its impact on human immunodeficiency virus-related wasting. Semin Oncol 1998,25:92-97.
12. Suva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12:1645-1651.
13. Shevitz A, Spiegelman D, French J, et al. Increased resting energy expenditure (REE) is associated with increased plasma HIVRNA. 12th World AIDS Conference. Geneva, 1998.
14. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern A.fed1998, 129:18-26.
15. Oster MH, Enders SR, Samuels S), et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994, 121:400-408.
16. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associatcd wasting. A randomized, placebo-controlled trial. Serostim Study Croup. Ann Intern Med 1996, 125:873-882.
17. Suttmann U, Ockenga J, Hoogestraat L, et al. Resting energy expenditure and weight loss in human immunodeficiency virus-infected patients. Metabolism 1993, 42:1173-1179.
18. Sharpstone DR, Murray CP, Ross HM, et al. Energy balance in asymptomatic HIV infection./WDS 1996, 10:1377-1384.
19. Sharpstone DR, Ross HM, Gazzard BG. The metabolic response to opportunistic infections in AIDS. AIDS 1996, 10:1529-1533.
20. Melchior JC, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am I Clin Nutr 1991, 53:437-441.
21. Melchior JC, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. Ami Clin Nutr 1993, 57:614-619.
22. Hoffman WE, Berkowitz R, McDonald T, Mass F. Ultra-rapid opioid detoxification increases spontaneous ventilation. J Clin Anesth 1998, 10:372-376.
23. Favier R, Caceres E, Koubi H, Sempore B, Sauvain M, Spielvogel H. Effects of coca chewing on hormonal and metabolic responses during prolonged submaximal exercise. ] Appl Physiol 1996, 80:650-655.
24. Renaud AM, Cormier Y. Acute effects of marihuana smoking on maximal exercise performance. Med Sei Sports Exerc 1986, 18:685-689.
25. Hoy JF, Flanigan TP. Wasting associated with cocaine and heroin use in patients infected with human immunodeficiency virus. Clin Infect Dis 1994, 19:209-210.
26. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280:78-86.
27. Patick AK, Mo H, Markowitz M, et aJ. Antiviral and resistance studies of AGI 343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297.
28. Lukaski HC, Johnson PE. A simple, inexpensive method of determining total body water using a tracer dose of D2O and infrared absorption of biological fluids. Am I Clin Nutr 1985, 41:363-370.
29. Shizgal HM. Validation of the measurement of body composition from whole body bioelectric impedance. Infusiomtherapie 1990, 17(Suppl. 3):67-74.
30. Koller DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am ] Clin Nutr 1996, 64:4895-4975.
31. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. Nutrition 1990, 6:213-221.
32. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cylometry. Clïn Immunol Immunopathol 1989, 52:48-60.
33. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal WklyRep 1998, 47:1-111.
34. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol 1998, 25:76-81.
35. Dulloo AC, Jacquet J, Cirardier L. Autoregulation of body composition during weight recovery in human: the Minnesota Experiment revisited. Int ! Obes Related Metao Disord 1996, 20:393-405.
36. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121:393-399.
37. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:865-872.
38. Cold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996, 10:745-752.
39. Mulligan K, Tai VW, Schambelan M. Energy expenditure in human immunodeficiency virus infection. N Engt ) Med 1997, 336:70-71.
40. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998,12:1735-1744.